Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

BTG launches company to develop breakthrough technology to treat broad array of neurological conditions

BTG : 13 October, 2006  (Company News)
London, UK: BTG, the global technology commercialisation company, today launched KetoCytonyx, Inc., a company created to develop BTG
KetoCytonyx will develop new treatments for acute brain injury such as stroke and chronic neurodegenerative conditions such as Alzheimer’s disease. Initially the company will be based at BTG’s office in Pennsylvania, USA. BTG will license the core intellectual property to KetoCytonyx and will provide intellectual property management, development planning, as well as general management and commercial strategy advice, in exchange for a majority equity stake. It will also initially invest £240,000 to create the company, with further investment anticipated in the near future.

The ketone technology has been developed from intellectual property obtained by BTG from Dr Richard Veech in the US and from a Japanese company, Shimizu Pharmaceutical Co. Ltd. Ketone bodies are an alternative energy source, which appear to confer neurological benefits in disease models. Previous research has shown that high levels of ketones can also modify the course of neurological diseases, for example childhood epilepsy. KetoCytonyx will build on this research, to develop proprietary formulations of ketone body products for acute and chronic therapy.

Initially, members of BTG’s Health, Medical and BioTechnologies Management team will manage the KetoCytonyx project. An early objective will be to recruit key executives into management roles in the company. A scientific advisory board has also been formed to advise the company on the development of the technologies. Professor George Cahill, Emeritus Professor, Harvard University Medical School, will chair this board. Professor Cahill has been active in this area for more than 30 years.

BTG’s Director of Health, Medical and BioTechnologies, Dr. Geoffrey Porges, said:

'The launch of KetoCytonyx is an opportunity for BTG to develop a unique technology derived from two sources in very important medical indications. We believe this technology could revolutionise treatment for sufferers of stroke, head trauma and neurodegenerative diseases around the world. It could also potentially reduce both the future costs and mortality rates associated with these devastating diseases.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo